How are drug companies responding and adapting to the inexorable pull towards the patient-centric world? Patient centricity has been a buzz word for a couple of years now and it is high time we assessed the impact it is having on pharma. Patient-centric pharma: Advancing the New Business Model reveals how success can be achieved and provides food for thought on various ways to place patients firmly at the heart of your business and achieve commercially beneficial outcomes. Based on interviews with 10 experts at the cutting edge of the patient revolution, this report lifts the lid on this business-critical area.

Why patient centricity matters for pharma

The clock cannot be turned back on patient empowerment; but what can change is how pharma responds. For some, it has already proved to be an opportunity to differentiate and edge ahead. What is clear is that there is no single blueprint for success and that the evolving landscape continues to offer plenty of opportunities for competitive advantage. Some will inevitably be left behind as the world moves on. But for those that genuinely engage with patients, there is much to gain.

Report Features

Assessment of the factors driving the shift towards a patient-centric business model as well as the expectations placed on pharma from various stakeholders.

Detailed discussion of the key challenges and barriers facing pharmaceutical companies at various points on the patient centricity journey – plus expert views on how to address them.

The latest thinking on multiple patient-centric structures and strategies with insight into the opportunities arising as new approaches take hold.

Clarity on how to bring about transformation including practical ideas, case studies and expert guidance on making the transition from brand focus to patient focus.

Key Benefits

Provides inspiration for long term plans: Improve understanding of the many significant opportunities that arise when patient-centricity moves up the priority list.

Highlights the operational changes required: Consider various business models; find out the core elements that apply to all; hear which tools have helped others and why.

Bolsters the business case: Read compelling arguments for gaining senior management support and business investment as well as planning operational restructuring and IT transformation.

Puts decision-makers on the same page: Ensure all areas of your organisation understand the background and route to firmly embedding a patient-centric strategy.

Key Questions Answered By This Report

Who has a role to play? Is patient focus a departmental or company-wide strategy? Is it just about patients or should pharma also engage with family members, carers and others?

What are the commercial benefits? Are there key metrics to have in place to keep track of progress? What does success look like?

How is the concept of patient centricity similar to ethics within pharma? What can be learned from reviewing how an ethical stance is accepted and embedded across the business?

When does the patient become most important? At what point in the product lifecycle should pharma seek to engage patients? How should engagement take place?

Expert Views

Dr Anne Beal, MD, Chief Patient Officer at Sanofi

Pamela Bennett, Executive Director Patient and Professional Relations at Purdue Pharma, US

Dr Neil Croft, PhD, Senior Manager, Advisory Services at Kinapse, consultants on capability building and operational services to the life sciences industry

3 Key Quotes

“One of the biggest challenges is the structure of pharmaceutical companies. They're looking through the lens of a brand trying to identify what its competitor's doing, rather than truly looking at it from the patient perspective. That's the challenge that needs to be overcome if pharma is really going to become patient centred.”Richard Jones, The Earthworks

“People want to understand what it means for them in their day-to-day work. They may hear that the company is patient-centric but they think ‘I’m working in finance for example, and it doesn't mean anything for me’. So, companies need to make it real for people there, or in manufacturing for example.”Dr Neil Croft, Kinapse

“It's important to recognise that patient engagement is critical and we need to incorporate it early in the development process and have it aligned across pharma functions.”Dr Tehseen Salimi, AstraZeneca

Who will benefit from this report?

Patient affairs and patient interaction leads

Senior leadership teams and key decision-makers

Marketing departments

Advocacy and government affairs specialists

Medical affairs teams

Digital innovation and IT decision-makers

Trial designers and managers

Content Highlights

The rising tide of patient centricity within healthcare and pharma

Changes in the environment trigger the need to revise the business model

Companies’ responses to adoption of patient centricity vary

Patients speak up

Key factors driving the change to patient-centric business models

Informed patients

Healthcare accountability

Patients can be payers

Patient-centric outcomes are instrumental in payer and reimbursement decisions

Our information rich society has created more informed and vocal end users which means that patients have taken their place at the table and can no longer be ignored. Payers are also demanding proof of outcomes, which can only come from patient interaction. How are drug companies responding and adapting to the inexorable pull towards a patient-centric world? And how can your business move further along the patient focus spectrum?

Patient-centric pharma: Advancing the New Business Model reveals how success can be achieved and provides food for thought on various ways to place patients firmly at the heart of your business and achieve commercially beneficial outcomes. Based on interviews with 10 experts at the cutting edge of the patient revolution, this report lifts the lid on this business-critical area.

Report Features

Assessment of the factors driving the shift towards a patient-centric business model as well as the expectations placed on pharma from various stakeholders.

Detailed discussion of the key challenges and barriers facing pharmaceutical companies at various points on the patient centricity journey – plus expert views on how to address them.

The latest thinking on multiple patient-centric structures and strategies with insight into the opportunities arising as new approaches take hold.

Clarity on how to bring about transformation including practical ideas, case studies and expert guidance on making the transition from brand focus to patient focus.

Key Benefits

Provides inspiration for long term plans: Improve understanding of the many significant opportunities that arise when patient-centricity moves up the priority list.

Highlights the operational changes required: Consider various business models; find out the core elements that apply to all; hear which tools have helped others and why.

Bolsters the business case: Read compelling arguments for gaining senior management support and business investment as well as planning operational restructuring and IT transformation.

Puts decision-makers on the same page: Ensure all areas of your organisation understand the background and route to firmly embedding a patient-centric strategy.

Why patient centricity matters for pharma

The clock cannot be turned back on patient empowerment; but what can change is how pharma responds. For some, it has already proved to be an opportunity to differentiate and edge ahead. What is clear is that there is no single blueprint for success and that the evolving landscape continues to offer plenty of opportunities for competitive advantage. Some will inevitably be left behind as the world moves on. But for those that genuinely engage with patients, there is much to gain.

Key Questions Answered By This Report

Who has a role to play? Is patient focus a departmental or company-wide strategy? Is it just about patients or should pharma also engage with family members, carers and others?

What are the commercial benefits? Are there key metrics to have in place to keep track of progress? What does success look like?

How is the concept of patient centricity similar to ethics within pharma? What can be learned from reviewing how an ethical stance is accepted and embedded across the business?

When does the patient become most important? At what point in the product lifecycle should pharma seek to engage patients? How should engagement take place?

Expert Views

Dr Anne Beal, MD, Chief Patient Officer at Sanofi

Pamela Bennett, Executive Director Patient and Professional Relations at Purdue Pharma, US

Dr Neil Croft, PhD, Senior Manager, Advisory Services at Kinapse, consultants on capability building and operational services to the life sciences industry

3 Key Quotes

“One of the biggest challenges is the structure of pharmaceutical companies. They're looking through the lens of a brand trying to identify what its competitor's doing, rather than truly looking at it from the patient perspective. That's the challenge that needs to be overcome if pharma is really going to become patient centred.”Richard Jones, The Earthworks

“People want to understand what it means for them in their day-to-day work. They may hear that the company is patient-centric but they think ‘I’m working in finance for example, and it doesn't mean anything for me’. So, companies need to make it real for people there, or in manufacturing for example.”Dr Neil Croft, Kinapse

“It's important to recognise that patient engagement is critical and we need to incorporate it early in the development process and have it aligned across pharma functions.”Dr Tehseen Salimi, AstraZeneca

Who will benefit from this report?

Patient affairs and patient interaction leads

Senior leadership teams and key decision-makers

Marketing departments

Advocacy and government affairs specialists

Medical affairs teams

Digital innovation and IT decision-makers

Trial designers and managers

Content Highlights

The rising tide of patient centricity within healthcare and pharma

Changes in the environment trigger the need to revise the business model

Companies’ responses to adoption of patient centricity vary

Patients speak up

Key factors driving the change to patient-centric business models

Informed patients

Healthcare accountability

Patients can be payers

Patient-centric outcomes are instrumental in payer and reimbursement decisions